Insulet Corporation $PODD Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC reduced its position in Insulet Corporation (NASDAQ:PODD) by 48.4% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 25,214 shares of the medical instruments supplier’s stock after selling 23,655 shares during the quarter. Intech Investment Management LLC’s holdings in Insulet were worth $7,167,000 at the end of the most recent reporting period.

Several other hedge funds have also recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Insulet by 1.0% in the 3rd quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after purchasing an additional 87,845 shares during the last quarter. Geode Capital Management LLC raised its stake in Insulet by 2.1% in the 4th quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after purchasing an additional 41,019 shares during the last quarter. Northern Trust Corp raised its stake in Insulet by 0.5% in the 3rd quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock valued at $218,945,000 after purchasing an additional 3,618 shares during the last quarter. Qube Research & Technologies Ltd raised its stake in Insulet by 37.3% in the 3rd quarter. Qube Research & Technologies Ltd now owns 574,365 shares of the medical instruments supplier’s stock valued at $177,324,000 after purchasing an additional 156,009 shares during the last quarter. Finally, Nordea Investment Management AB raised its stake in Insulet by 35.0% in the 4th quarter. Nordea Investment Management AB now owns 551,133 shares of the medical instruments supplier’s stock valued at $157,128,000 after purchasing an additional 142,922 shares during the last quarter.

Wall Street Analyst Weigh In

A number of analysts have issued reports on the company. The Goldman Sachs Group reaffirmed a “buy” rating and issued a $205.00 target price on shares of Insulet in a research note on Wednesday. Benchmark reaffirmed a “buy” rating on shares of Insulet in a research note on Wednesday. Wall Street Zen raised Insulet from a “buy” rating to a “strong-buy” rating in a research note on Saturday, May 9th. Jefferies Financial Group cut their target price on Insulet from $400.00 to $360.00 in a research note on Thursday, May 7th. Finally, William Blair assumed coverage on Insulet in a research note on Wednesday, May 20th. They issued an “outperform” rating for the company. Twenty-one equities research analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $252.04.

Insulet Stock Performance

NASDAQ PODD opened at $144.94 on Friday. The stock has a market cap of $10.04 billion, a PE ratio of 33.71, a P/E/G ratio of 1.15 and a beta of 1.20. The company has a current ratio of 2.49, a quick ratio of 1.81 and a debt-to-equity ratio of 0.71. Insulet Corporation has a twelve month low of $140.63 and a twelve month high of $354.88. The stock has a fifty day simple moving average of $183.55 and a 200-day simple moving average of $245.30.

Insulet (NASDAQ:PODD) last released its quarterly earnings results on Wednesday, May 6th. The medical instruments supplier reported $1.42 earnings per share for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million during the quarter, compared to analysts’ expectations of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The company’s revenue was up 33.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.02 EPS. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities analysts anticipate that Insulet Corporation will post 6.44 earnings per share for the current year.

Insulet Company Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.